mesalamine/sodium hyaluronate (IBD98-M) / Holy Stone Healthcare - LARVOL DELTA

Together with Heshentang Biotechnology, the new drug successfully passed the phase II clinical trial approval in China [Google translation] (Yahoo Sports) - "Gongxin-KY and Heshentang Biotech jointly developed the new drug IBD98-M for the treatment of inflammatory bowel disease (Inflammatory bowel disease, IBD), which officially passed the approval of the Phase II clinical trial of NMPA of the State Drug Administration of China. In the future, the two companies will Funds and manpower will be jointly invested in this phase II clinical trial, and Co-Trust-KY will also provide rich experience and contacts in clinical trials in China in the past and strive to assist in the smooth execution of this clinical trial."

New P2 trial • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

He Biotech: (Supplementary Warning) The company and Gongxin Pharmaceutical Technology Co., Ltd. signed the “IBD98-M Phase II Cooperation Agreement for the Implementation of Clinical Trials in China“ [Google translation] (Anue.com) - "The company cooperates with Gongxin Pharmaceutical to implement Phase II of the clinical trial of IBD98-M in China...Invest funds and manpower in clinical trial cases; Gongxin Pharmaceutical and provide it with a wealth of clinical trials...Work together to complete the IBD98-M clinical trial phase II, and use the clinical trial results to seek cooperation with Chinese and international medicine."

Licensing / partnership • Immunology • Inflammatory Bowel Disease